Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

GNI/Shanghai Genomics to Start China Clinical Trials of Liver Drug

publication date: Nov 21, 2007
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
GNI Ltd received an Investigational New Drug approval of F351, its novel treatment for liver fibrosis/cirrhosis, a currently unmet need. Shanghai Genomics, the China-based affiliate of GNI, is preparing for a Phase I clinical trial of F351. Two weeks ago, Shanghai Genomics was granted a patent in China for the drug. The business offices for GNI are in Tokyo, but R&D is carried out in Fukuoka (Japan), Cambridge (UK) and China. It has an intellectual property office in San Jose, California, and its clinical trial operations are carried out through Shanghai Genomics, located in the Zhangjiang Hi-Tech Park of Shanghai. More details...

Stock Symbol: (TOKYO: 2160)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...